GlassScriptPhysician profile
Robbilyn Verges
NPI 1376279356
$1,435.89
in general payments reported to CMS, 2019-2025
9 companies · $385 in 2025
The $385 reported for 2025 was more than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $169 · 2023: $747 · 2024: $135 · 2025: $385.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,111 · Entertainment: $156.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,111.10 |
| Entertainment | $156.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $390.88 | 2023-2025 | Infuse, Infuse Multifocal, Biotrue One Day |
| Optos, INC. | $277.19 | 2022-2025 | Panoramic Ophthalmoscope, Oct Ophthalmoscope, Nfc-700 |
| Dompe US, INC. | $189.70 | 2023-2025 | Oxervate |
| Alcon Vision LLC | $171.93 | 2022-2024 | Clareon, Total30 |
| Tarsus Pharmaceuticals, INC. | $115.83 | 2024 | Xdemvy |
| Johnson & Johnson Vision Care, INC. | $112.29 | 2023 | Acuvue |
| Sun Pharmaceutical Industries INC. | $100.00 | 2023 | Cequa |
| Oyster Point Pharma, INC. | $63.93 | 2022-2023 | Tyrvaya |
| Coopervision INC. | $14.14 | 2025 | Biofinity Contact Lens |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robbilyn Verges listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.